COVA-420

N/A

Report date: 2026/03/19 16:59:35

Base Information

Drug NameCOVA-420
Drug Alias Namebispecific proteins (Covagen/Mitsubishi Tanabe Pharma)FynomAbs (Covagen/Mitsubishi Tanabe Pharma)anti-CD3/anti-HER2 bispecific T-cell engager (Covagen/Mitsubishi Tanabe Pharma)COVA-420
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerlandJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCovagen Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMitsubishi Tanabe Pharma CorpCovagen Ag
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A